Danaher Co. (NYSE:DHR) Shares Acquired by Confluence Wealth Services Inc.

Confluence Wealth Services Inc. increased its stake in shares of Danaher Co. (NYSE:DHR) by 4.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,904 shares of the conglomerate’s stock after purchasing an additional 120 shares during the period. Confluence Wealth Services Inc.’s holdings in Danaher were worth $713,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. FMR LLC raised its holdings in shares of Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after acquiring an additional 3,217,631 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Danaher by 3.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after purchasing an additional 148,251 shares in the last quarter. Fisher Asset Management LLC raised its stake in Danaher by 2.6% in the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock valued at $1,265,725,000 after purchasing an additional 116,299 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares in the last quarter. Finally, Montrusco Bolton Investments Inc. grew its holdings in shares of Danaher by 0.6% during the fourth quarter. Montrusco Bolton Investments Inc. now owns 1,715,826 shares of the conglomerate’s stock worth $382,936,000 after buying an additional 9,942 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of NYSE DHR opened at $211.92 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. Danaher Co. has a 1-year low of $210.04 and a 1-year high of $281.70. The company has a market capitalization of $153.07 billion, a price-to-earnings ratio of 40.14, a PEG ratio of 2.80 and a beta of 0.83. The business has a 50-day moving average of $234.50 and a 200-day moving average of $252.68.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the previous year, the firm posted $2.09 earnings per share. On average, equities analysts anticipate that Danaher Co. will post 7.77 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.51%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is 20.45%.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts recently issued reports on DHR shares. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. JPMorgan Chase & Co. decreased their price objective on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Guggenheim assumed coverage on Danaher in a research note on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price for the company. Scotiabank initiated coverage on Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target on the stock. Finally, Stephens restated an “overweight” rating and issued a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.